UBS Group’s Transphorm, Inc. Common Stock TGAN Stock Holding History

UBS Group’s Portfolio TGAN Stock Details TGAN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-331,654	Closed	-$1.63M	–	10339
2024 Q1	$1.63M	Buy	331,654 +300,277	+957%	+$1.43M	﹤0.01%	4140
2023 Q4	$115K	Buy	31,377 +17,733	+130%	+$48.6K	﹤0.01%	6098
2023 Q3	$30.3K	Sell	13,644 -1,951	-13%	-$5.45K	﹤0.01%	6583
2023 Q2	$53K	Sell	15,595 -3,943	-20%	-$14.2K	﹤0.01%	6440
2023 Q1	$78K	Buy	19,538 +15,356	+367%	+$67.6K	﹤0.01%	6115
2022 Q4	$22.8K	Buy	+4,182	New	+$24.6K	﹤0.01%	7522

UBS Group's TGAN Position: Q2 2024 in Review

UBS Group sold out of Transphorm, Inc. Common Stock (TGAN) in Q2 2024, closing a stake of 331,654 shares — an estimated $1.63M sold.

UBS Group first reported a position in TGAN in Q4 2022 and held it in 6 quarters. The position peaked at $1.63M in Q1 2024. 0 funds tracked by Wall St. Rank hold TGAN as of Q2 2024.

UBS Group reported no remaining Transphorm, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
UBS Group sold 331,654 Transphorm, Inc. Common Stock shares in Q2 2024, an estimated $1.63M.
UBS Group first reported a position in Transphorm, Inc. Common Stock in Q4 2022 and held it in 6 quarters.
UBS Group's Transphorm, Inc. Common Stock position peaked at $1.63M in Q1 2024.
0 funds tracked by Wall St. Rank held Transphorm, Inc. Common Stock as of Q2 2024.

Based on UBS Group's 13F filing for Q2 2024, filed 14 Aug 2024.